HIV-1
Conditions
Interventions
Case series:NA
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients (aged 12 years and older with body weights of at least 35 kg) who are Chinese and living in China; 2. Patients with HIV-1 infection eligible for treatment with E/C/F/TAF tablet (Genvoya) or F/TAF tablet (Descovy) as indicated in the approved prescribing information; 3. Patients who have been informed of all pertinent aspects of the study and have voluntarily signed an informed consent form (patients under 18 years of age must also have signed consent from either parents or a legally authorized representative (i.e., a legal guardian) who has been informed of all pertinent aspects of the study)."
Exclusion criteria
Exclusion criteria: 1. Patients treated with E/C/F/TAF tablet (Genvoya) or F/TAF tablet (Descovy) outside of the approved prescribing information in China; 2. Concurrent participation in a clinical trial of HIV treatment (except trials not testing investigational medicinal products); 3. Patients who have a contraindication as indicated under prescribing information: 4. Patients planning on leaving the country for an extended period during the study period; 5. Patients deemed by the investigator to be unlikely to maintain regular medical follow-up through at least 48 weeks".
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of adverse events;Treatment success (Proportion of patients achieving virologic response at 48 weeks after the start of treatment); | — |
Countries
China
Contacts
Public ContactAlan Zhao
Shanghai Public Health Clinical Center
Outcome results
None listed